The current study aimed to explore the subjective effects of psychedelics when used alongside cannabis.
Trauma exposure across the lifespan produces risks for posttraumatic stress disorder (PTSD), depression, anxiety, as well as global disability in functioning. This retrospective clinical chart review is the first of its kind to assess the utility of sublingual ketamine-assisted body-centered psychotherapy in trauma-exposed patients in a real world clinic setting.
Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike any treatments currently available. Not only do they produce sustained therapeutic effects following a single administration, but they also appear to have broad therapeutic potential, demonstrating efficacy for treating depression, post-traumatic stress disorder (PTSD), anxiety disorders, substance abuse disorder, and alcohol use disorder, among others. Psychedelics belong to a more general class of compounds known as psychoplastogens, which robustly promote structural and functional neural plasticity in key circuits relevant to brain health. Here we discuss the importance of structural plasticity in the treatment of neuropsychiatric diseases, as well as the evidence demonstrating that psychedelics are among the most effective chemical modulators of neural plasticity studied to date.
Terrence McKenna famously proposed the Stoned Ape Theory which suggests that psychedelic mushrooms catalyzed human evolution by enhancing visual acuity (low dose), sexual activity (moderate dose), and visionary experience (high dose). Moreover, he believed that the fungi likely brought about self-reflection and language. This article looks at new evidence that lends further support to the vital role that psilocybin might have played in human evolution.
There are numerous critical periods throughout the maturation of a human. For example, there are developmental periods during which language is most readily learned, physical sensations are developed, emotional responses are mastered, and movement is refined. The enhanced neuroplasticity that allows for these critical periods doesn't last forever, so once a period is passed it's especially difficult to learn a new skill. This hypothesis posits that psychedelics may temporarily reinstate this plasticity, sensitizing adults to environmental inputs and facilitating the relearning process that can be optimized via psychotherapy.
Ketamine can address both physical and psychological pain. In fact, it's widely used as an analgesic. Many people with depression also experience physical pain. This study found that ketamine had a stronger antidepressant effect in patients with treatment-resistant depression (TRD) and pain than in patients with TRD alone.
After languishing for decades from legal restrictions and stigma, research into psychedelic drugs is exploding – with the encouragement of the Food and Drug Administration. Recent clinical trial successes suggest some long-banned drugs could soon be authorized as treatments for debilitating illnesses. Yet because of these drugs’ history, FDA approval would be just one important step in a complex process to transform these compounds into therapies. Incorporating psychedelic drugs into clinical practice will require peeling back multiple layers of legal prohibition, clarifying prescribing guidelines, and developing treatment models that work for drug-makers, physicians, and payers.